Evidence map›Paper›PMID 40078289›Full record

ArticleFrontiers in pharmacology2025

Myositis of pterygoid muscles and superior ophthalmic vein and cavernous sinus thrombosis in active Crohn's disease undergoing ustekinumab treatment: a case report and literature review.

Robbe Winters, Sara Kaut, Dries Govaerts, Aaron De Poortere, Ilse Mombaerts, Ilse Hoffman, Robin Willaert, Karen van Hoeve

Abstract readCase Reports
In one paragraph

Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Robbe WintersDepartment of Oral and Maxillofacial Surgery, University Hospitals Leuven, Leuven, Belgium.
Sara KautDepartment of Pediatric Gastroenterology and Hepatology and nutrition, University Hospitals Leuven, KU Leuven, Leuven, Belgium.
Dries GovaertsDepartment of Oral and Maxillofacial Surgery, University Hospitals Leuven, Leuven, Belgium.
Aaron De PoortereDepartment of Oral and Maxillofacial Surgery, University Hospitals Leuven, Leuven, Belgium.
Ilse MombaertsDepartment of Ophthalmology, University hospitals Leuven, Leuven, Belgium.
Ilse HoffmanDepartment of Pediatric Gastroenterology and Hepatology and nutrition, University Hospitals Leuven, KU Leuven, Leuven, Belgium.
Robin WillaertDepartment of Oral and Maxillofacial Surgery, University Hospitals Leuven, Leuven, Belgium.
Karen van HoeveDepartment of Pediatric Gastroenterology and Hepatology and nutrition, University Hospitals Leuven, KU Leuven, Leuven, Belgium.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Myositis is a rare extra-intestinal presentation in patients with inflammatory bowel diseases (IBD), and its occurrence has only been described in a few case reports. However, it is essential to consider other potential causes as patients with IBD are more susceptible to infections due to their immunocompromised status, which may also be exacerbated by immunosuppressive drugs contributing to myositis. Our case highlights the complexity and challenges in diagnosing and managing myositis in patients with IBD as well as a review of the literature. Case report: We report the case of a 17-year-old girl with active Crohn's disease (CD) undergoing ustekinumab (UST) treatment. She presented with sudden onset of pain and rapid progressive swelling of both jaws, along with eyelid swelling, blurred vision, and diplopia. Radiologic imaging revealed myositis affecting the pterygoid muscles, combined with thrombosis of the left superior ophthalmic vein and (partially) of the left cavernous sinus. Symptoms resolved completely after stopping UST treatment and initiating corticosteroids and enoxaparine. Discussion: Our report accounts for the second patient described in literature with myositis associated with CD while being treated with UST. The causal factor remains speculative, as both active CD and UST treatment may contribute to this complication. Sharing clinical experiences and reporting possible adverse events to regulatory agencies can enhance our understanding of rare complications and improve patient outcomes by providing therapeutic strategies.

Indexed as

case reportinflammatory bowel diseasesmyositispediatricsustekinumab

Identifiers

PMID40078289
PMCPMC11897002

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.